The effect of silver fibre gloves on Raynaud's phenomenon in patients with systemic sclerosis: a double-blind randomized crossover trial

被引:3
|
作者
Liem, Sophie I. E. [1 ]
Hoekstra, Eva M. [1 ]
Bonte-Mineur, Femke [2 ]
Checa, Cesar Magro [3 ]
Schouffoer, Anne [4 ]
Allaart, Cornelia F. [1 ]
Huizinga, Tom W. J. [1 ]
Bergstra, Sytske Anne [1 ]
de Vries-Bouwstra, Jeska K. [1 ]
机构
[1] Leiden Univ, Dept Rheumatol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Maasstad Ziekenhuis, Dept Rheumatol & Clin Immunol, Rotterdam, Netherlands
[3] Zuyderland Med Ctr, Dept Rheumatol, Heerlen, Netherlands
[4] Haga Ziekenhuis, Dept Rheumatol, The Hague, Netherlands
关键词
SSc; scleroderma; RP; silver fibre gloves; crossover trial; MINIMALLY IMPORTANT DIFFERENCE; QUALITY-OF-LIFE; SCLERODERMA; MANAGEMENT;
D O I
10.1093/rheumatology/keac243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Silver fibre gloves transport heat from the palm to the fingers, possibly reducing the burden of RP in SSc patients. We aim to evaluate the clinical efficiency of this intervention. Methods. A multicentre, double-blind, randomized trial was performed, accounting for interindividual differences and external factors using a crossover design. Patients were randomized in two groups: group 1 wore 8% silver fibre gloves in period 1 and normal gloves in period 2 and group 2 vice versa. Each period lasted 6 weeks. The primary outcome was the Raynaud Condition Score (RCS) over time (minimal clinical important difference 1.4), assessed three times per week using an online questionnaire. Secondary outcomes included vascular complications and Scleroderma-Health Assessment Questionnaire (SHAQ). Outcomes were evaluated before unblinding using linear mixed models. Results. A total of 85 SSc patients were included, with 76 completing the study. The mean RCS during 2 weeks before the study (i.e. without gloves) was 6.4 (s.D. 1.6). Both with silver fibre gloves and normal gloves the mean RCS decreased to 3.9 (s.D. 2.3) with a similar course over time. There was no difference in mean RCS over time between the type of gloves [beta=0.067 (95% CI -0.006, 0.19)]. Of secondary outcomes, total SHAQ [beta=0.036 (95% CI 0.026, 0.046)] was slightly higher with silver fibre gloves, which is clinically irrelevant. Three patients developed new digital ulcers with normal gloves vs one patient with silver fibre gloves [odds ratio 3.2 (95% CI 0.32, 31.1)]. Conclusions. Wearing gloves in SSc patients clearly decreases the RP burden. Our results do not support the hypothesis that increased heat transport of 8% silver fibre gloves is associated with less disease burden as measured in this study by the RCS compared with normal gloves.
引用
收藏
页码:SI74 / SI81
页数:8
相关论文
共 50 条
  • [32] EFFECT OF SARPOGRELATE FOR RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
    Makino, T.
    Jinnin, M.
    Kajihara, I.
    Makino, K.
    Ihn, H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S79 - S79
  • [33] Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis
    Cutolo, Maurizio
    Smith, Vanessa
    Hysa, Elvis
    LANCET RHEUMATOLOGY, 2024, 6 (10): : e655 - e657
  • [34] Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial
    Shenoy, Padmanabha D.
    Kumar, Sudeep
    Jha, Lalan K.
    Choudhary, Sunil K.
    Singh, Uttam
    Misra, Ramnath
    Agarwal, Vikas
    RHEUMATOLOGY, 2010, 49 (12) : 2420 - 2428
  • [35] Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial
    Gilbert, DL
    Sethuraman, G
    Sine, L
    Peters, S
    Salle, FR
    NEUROLOGY, 2000, 54 (06) : 1310 - 1315
  • [36] ORAL NIFEDIPINE TREATMENT FOR RAYNAUD PHENOMENON SECONDARY TO SYSTEMIC-SCLEROSIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    THOMAS, RHM
    RADEMAKER, M
    GRIMES, SM
    KOVACS, IB
    MACKAY, A
    BOWCOCK, S
    COOKE, ED
    KIRBY, JDT
    BRITISH JOURNAL OF DERMATOLOGY, 1986, 115 : 37 - 38
  • [37] Discontinuing long-term iloprost treatment for Raynaud's phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study
    Bali, G.
    Schwantzer, G.
    Aberer, F.
    Kraenke, B.
    Aberer, E.
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2011, 20 (01): : 13 - 21
  • [38] Oral iloprost for Raynaud phenomenon (RP) in systemic sclerosis (SSC): a placebo-controlled, double-blind study.
    Wigley, FM
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 558 - 558
  • [39] THERAPY WITH NIFEDIPINE IN ASTHMA - A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL
    LIDJI, M
    MOLHO, M
    CHAGNAC, A
    KATZ, I
    BENZARAY, S
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (01): : 1 - 4
  • [40] Effect of sera from patients with systemic sclerosis and Raynaud's phenomenon on neutrophil apoptosis
    Naylor, Emma J.
    Cross, Andrew
    Barnes, Theresa
    Anderson, Marina E.
    Pazmany, Laszlo
    Edwards, Steven W.
    Moots, Robert J.
    RHEUMATOLOGY, 2008, 47 : II88 - II88